ID   JJN-1
AC   CVCL_L066
SY   JJN1
DR   Wikidata; Q54898952
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2495201;
RX   PubMed=10936422;
CC   Population: Caucasian.
CC   Characteristics: Produces IgA1 kappa.
CC   Characteristics: IL6 dependent.
CC   Doubling time: 10 days (PubMed=2495201).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 13
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2495201;
RA   Jackson N., Lowe J., Ball J., Bromidge E., Ling N.R., Larkins S.,
RA   Griffith M.J., Franklin I.M.;
RT   "Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2)
RT   which proliferate in response to B cell stimulatory factor 2.";
RL   Clin. Exp. Immunol. 75:93-99(1989).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//